Gujarat Kidney Super Speciality Ltd vs Max Healthcare Institute Ltd Stock Comparison
Gujarat Kidney Super Speciality Ltd vs Max Healthcare Institute Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 176.95 as of 23 Oct 15:30
. The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Max Healthcare Institute Ltd changed from 55.6 on March 2022 to 64.9 on March 2026 . This represents a CAGR of 3.14% over 5 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Max Healthcare Institute Ltd changed from ₹ 19903 crore on March 2021 to ₹ 93581 crore on March 2026 . This represents a CAGR of 29.43% over 6 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Max Healthcare Institute Ltd for the Jun '26 is ₹ 2406 crore as compare to the Mar '26 revenue of ₹ 2190 crore. This represent the growth of 9.86% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Max Healthcare Institute Ltd for the Jun '26 is ₹ 638.97 crore as compare to the Mar '26 ebitda of ₹ 654.26 crore. This represent the decline of -2.34% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77%
The net profit of Max Healthcare Institute Ltd changed from ₹ 236.27 crore to ₹ 322.96 crore over 9 quarters. This represents a CAGR of 14.90%
The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Max Healthcare Institute Ltd changed from 13.98 % on March 2023 to 27.16 % on March 2026 . This represents a CAGR of 18.06% over 4 years .
About Gujarat Kidney & Super Speciality Ltd
Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad.
The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.
About Max Healthcare Institute Ltd
Max Healthcare Institute Limited was originally incorporated as 'Infinitum Technologies Private Limited' at New Delhi, India as a Private Limited Company dated June 18 ,2001.
Pursuant to a Fresh Certificate of Incorporation dated June 28, 2002, the name of Infinitum Technologies Private Limited' was changed to Max Healthcare Institute Private Limited'.
Thereafter, pursuant to a Special Resolution dated May 16, 2002 and a fresh Certificate of Incorporation dated October 18, 2002, the Company converted to a Public Limited, and name was changed to Max Healthcare Institute Limited'.
The Company is primarily engaged in provision of healthcare services through primary care clinics, multi speciality hospitals / medical centres and superspecialty Hospitals facilities.
The Company is a leading hospital chains in India with major concentration in North India consisting of a network of 22 network healthcare facilities, which includes BLK Hospital and BNH Hospital.
FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd
Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Max Healthcare Institute Ltd?
Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr while Market cap of Max Healthcare Institute Ltd is 79,519 Cr
What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd?
The stock performance of Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd?
As of October 25, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95. On the other hand, Max Healthcare Institute Ltd stock price is INR ₹817.0.
How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd compare?
To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Max Healthcare Institute Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.